𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

✍ Scribed by Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Meng-Feng Tsai; Ya-Chieh Hsu; Kuan-Yu Chen; Wen-Pin Su; Pan-Chyr Yang

Publisher
John Wiley and Sons
Year
2005
Tongue
French
Weight
161 KB
Volume
118
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Recently, mutations in the epidermal growth factor receptor (EGFR) gene in nonsmall cell lung cancer (NSCLC) patients were reported to correlate with gefitinib response. Less than 30% of NSCLC patients are surgically resectable; however, molecular analysis has to rely on nonsurgical diagnostic tissue samples. The objective of this study is to investigate EGFR mutation analysis on needle biopsy/aspiration samples and its correlations with gefitinib response and patients' survival. EGFR mutation was assessed from DNA of 63 paraffin‐embedded small needle biopsy/aspiration specimens from 62 patients with NSCLC treated with gefitinib. The peripheral blood lymphocyte DNA of the patients was sequenced to verify the EGFR mutation. EGFR mutations were found in 47% of 62 patients (60% of 20 CT‐guided biopsies, 44% of 18 ultrasound‐guided biopsies, 31% of 16 endoscopic biopsies and 44% of 9 effusion cell blocks). EGFR mutations were frequently present in females (p = 0.006) and never smokers (p = 0.04). Patients with EGFR mutations had a significantly better response rate compared to that of the nonmutation group (p < 0.001). Multivariate analysis showed that EGFR mutation (p < 0.001) and PS 0–1 (p = 0.02) were independently associated with a better response rate. Cox regression analysis showed that EGFR mutation was the independent prognostic factor for progression‐free survival (p = 0.008) and overall survival (p = 0.03). In conclusion, EGFR mutation analysis is feasible in needle biopsy/aspiration paraffin‐fixed specimens. EGFR mutation is an independent predictor of gefitinib response and survival in patients of advanced NSCLC treated by gefitinib. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Comparative analysis of epidermal growth
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer
✍ Takashi Sone; Kazuo Kasahara; Hideharu Kimura; Kazuto Nishio; Masayuki Mizuguchi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB 👁 1 views

## Abstract ## BACKGROUND. Because the investigation of epidermal growth factor receptor gene (__EGFR__) status as a predictor of gefitinib efficacy in Japanese patients has shown promise, the authors evaluated __EGFR__ mutations and gene amplification in biopsy specimens from Japanese patients wi

Epidermal growth factor receptor mutatio
Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer : Impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors
✍ Victor Cohen; Jason S. Agulnik; Celina Ang; Goulnar Kasymjanova; Gerald Batist; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 1 views

## Abstract ## BACKGROUND: Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) in patients with nonsmall cell lung cancer (NSCLC). ## METHODS: The authors tested the possibility that nucleoti

Detection of epidermal growth factor rec
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer
✍ Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 260 KB 👁 1 views

## Abstract The high frequency of epidermal growth factor receptor (__EGFR__) mutations in tyrosine kinase inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating __EGFR__ mutations in guiding the clinical use of __EGFR_

Epidermal growth factor receptor immunoh
Epidermal growth factor receptor immunohistochemistry : Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
✍ Fred R. Hirsch; Rafal Dziadziuszko; Nick Thatcher; Helen Mann; Claire Watkins; D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

## Abstract ## BACKGROUND The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall‐cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR)

Usefulness of monitoring the circulating
Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
✍ Nobuhisa Ishikawa; Noboru Hattori; Akihoto Yokoyama; Sonosuke Tanaka; Ryohei Nis 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 289 KB 👁 1 views

## Abstract Krebs von den Lungen‐6 (KL‐6) is a high molecular weight glycoprotein classified in the category of human MUC1 mucin. KL‐6 has been reported to serve as a sensitive marker for interstitial pneumonia; however, recent studies have suggested that it can also be used as a tumor marker as it